drugset / Trial / NCT04983550
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a multicenter, randomized, controlled, open-label, phase II study to evaluate the efficacy and safety of SG001 in combination with doxorubicin hydrochloride liposome injection in patients with platinum-resistant relapsed epithelial ovarian cancer.
Timeline
- Start
- 2021-09
- Primary completion
- 2023-01
- Completion
- 2024-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Enlonstobart | Monoclonal antibody | 240 mg | Intravenous |